CytomX Therapeutics financials
$2.75+2.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $68.4M | $26.9M | $59.5M | $71.6M | $15.0M |
| Gross profit | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $68.4M | $26.9M | $59.5M | $71.6M | $15.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M | -$116.0M | -$80.5M | -$141.5M | -$77.9M | -$46.3M | -$59.6M |
| Net income | -$20.4M | $31.9M | -$569.0K | -$99.3M | -$115.9M | -$64.8M | -$132.8M | -$84.6M | -$43.1M | -$58.9M |
| Net margin | −26.7% | 23.1% | −0.6% | −186.8% | −310.5% | −94.7% | −493.7% | −142.2% | −60.2% | −391.5% |
| Diluted EPS | $-0.15 | $0.38 | $-0.01 | $-1.51 | $-1.81 | $-1.40 | $-2.93 | $-2.03 | $-1.16 | $-1.63 |
| EBITDA | -$21.0M | $26.8M | -$4.3M | -$98.9M | -$116.0M | -$78.0M | -$138.9M | -$76.0M | -$44.6M | -$57.9M |
| Operating cash flow | -$75.6M | -$86.2M | -$56.0M | -$110.8M | -$119.0M | $5.3M | -$140.5M | -$75.5M | $170.4M | -$2.0M |
| Free cash flow | -$75.8M | -$86.5M | -$56.9M | -$112.5M | -$120.6M | $3.0M | -$144.0M | -$79.3M | $168.8M | -$4.2M |
| Diluted shares | 137.9M | 84.7M | 73.8M | 65.7M | 64.1M | 46.1M | 45.3M | 41.7M | 37.2M | 36.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.7M | $38.1M | $17.2M | $193.7M | $205.5M | $191.9M |
| Short-term investments | $124.4M | $62.6M | $157.3M | $0.00 | $99.7M | $124.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $151.6M | $120.5M | $201.8M | $260.9M | $339.4M | $358.7M |
| Total liabilities | $52.6M | $121.0M | $249.2M | $346.6M | $339.9M | $308.9M |
| Shareholders' equity | $99.0M | -$456.0K | -$47.4M | -$85.8M | -$459.0K | $49.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology